Microglial activation and dopamine terminal loss in early Parkinson's disease
- PMID: 15668962
- DOI: 10.1002/ana.20338
Microglial activation and dopamine terminal loss in early Parkinson's disease
Abstract
Neuroinflammatory glial response may contribute to degenerative processes in Parkinson's disease (PD). To investigate changes in microglial activity associated with changes in the presynaptic dopamine transporter density in the PD brain in vivo, we studied 10 early-stage drug-naive PD patients twice using positron emission tomography with a radiotracer for activated microglia [(11)C](R)-PK11195 and a dopamine transporter marker [(11)C]CFT. Quantitative levels of binding potentials (BPs) of [(11)C](R)-PK11195 and [(11)C]CFT in the nigrostriatal pathway were estimated by compartment analyses. The levels of [(11)C](R)-PK11195 BP in the midbrain contralateral to the clinically affected side were significantly higher in PD than that in 10 age-matched healthy subjects. The midbrain [(11)C](R)-PK11195 BP levels significantly correlated inversely with [(11)C]CFT BP in the putamen and correlated positively with the motor severity assessed by the Unified Parkinson's Disease Rating Scale in PD. In healthy subjects, the [(11)C](R)-PK11195 BP in the thalamus and midbrain showed an age-dependent increase. In vivo demonstration of parallel changes in microglial activation and corresponding dopaminergic terminal loss in the affected nigrostriatal pathway in early PD supports that neuroinflammatory responses by intrinsic microglia contribute significantly to the progressive degeneration process of the disease and suggests the importance of early therapeutic intervention with neuroprotective drugs.
Comment in
-
Hot spots: can positron emission tomography offer insights into the pathogenesis of PD?Ann Neurol. 2005 Feb;57(2):161-2. doi: 10.1002/ana.20382. Ann Neurol. 2005. PMID: 15668974 No abstract available.
Similar articles
-
Neuroinflammation in the living brain of Parkinson's disease.Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S200-4. doi: 10.1016/S1353-8020(09)70814-4. Parkinsonism Relat Disord. 2009. PMID: 20082990 Review.
-
Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography.Ann Neurol. 1999 May;45(5):601-10. Ann Neurol. 1999. PMID: 10319882
-
Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.Ann Neurol. 1999 Nov;46(5):723-31. doi: 10.1002/1531-8249(199911)46:5<723::aid-ana7>3.0.co;2-r. Ann Neurol. 1999. PMID: 10553989
-
Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET.J Nucl Med. 2010 Aug;51(8):1250-7. doi: 10.2967/jnumed.110.076802. Epub 2010 Jul 21. J Nucl Med. 2010. PMID: 20660377
-
Parkinson's disease: in vivo assessment of disease progression using positron emission tomography.Brain Res Mol Brain Res. 2005 Mar 24;134(1):24-33. doi: 10.1016/j.molbrainres.2004.09.028. Epub 2004 Nov 2. Brain Res Mol Brain Res. 2005. PMID: 15790527 Review.
Cited by
-
Translocator Protein 18 kDa (TSPO) Deficiency Inhibits Microglial Activation and Impairs Mitochondrial Function.Front Pharmacol. 2020 Jun 30;11:986. doi: 10.3389/fphar.2020.00986. eCollection 2020. Front Pharmacol. 2020. PMID: 32695005 Free PMC article.
-
Development of a new toolbox for mouse PET-CT brain image analysis fully based on CT images and validation in a PD mouse model.Sci Rep. 2022 Sep 22;12(1):15822. doi: 10.1038/s41598-022-19872-4. Sci Rep. 2022. PMID: 36138085 Free PMC article.
-
Osteopontin/secreted phosphoprotein-1 harnesses glial-, immune-, and neuronal cell ligand-receptor interactions to sense and regulate acute and chronic neuroinflammation.Immunol Rev. 2022 Oct;311(1):224-233. doi: 10.1111/imr.13081. Epub 2022 Apr 22. Immunol Rev. 2022. PMID: 35451082 Free PMC article. Review.
-
The Healing Effect of Human Milk Fat Globule-EGF Factor 8 Protein (MFG-E8) in A Rat Model of Parkinson's Disease.Brain Sci. 2018 Aug 31;8(9):167. doi: 10.3390/brainsci8090167. Brain Sci. 2018. PMID: 30200351 Free PMC article.
-
A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.J Parkinsons Dis. 2019;9(1):31-61. doi: 10.3233/JPD-181471. J Parkinsons Dis. 2019. PMID: 30400107 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical